Skip to content

Vor Biopharma VOR Short-Term Investments

Short-Term Investments at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$363M+18.2%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.75B+14.9%
Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
$483.59M+91.1%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%
Design Therapeutics, Inc. logo
Design Therapeutics, Inc.DSGN
$210.05M-2.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$57.01M

Other financials

Income statement

See full
Operating income-$35.2M-5.6%
Net income-$219.6M-576%
EPS (diluted)-$5.11+1.9%

Balance sheet

See full
Cash & equivalents$169.9M+239%
Total debt$2.9M-90.5%
Total equity-$150.4M-328%
Total assets$506.7M+364%

Cash flow

See full
Operating cash flow-$38.2M-23.1%
CapEx$48.0K-79.2%
Free cash flow-$38.3M-22.4%

Valuation

See full
Market cap$784.61M+2,513%
Enterprise value$617.68M+5,639%

Returns & leverage

See full
Return on equity-125.4%+671pp
Debt / equity0.5×+0.2×
Current ratio31.1×+27.3×

Where this comes from

Reported directly by Vor Biopharma in its filing.

Tagged under the XBRL concept us-gaap:MarketableSecuritiesCurrent.

The official record: Vor Biopharma’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vor Biopharma's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vor Biopharma's short-term investments?
Vor Biopharma (VOR) reported short-term investments of $321.65M in Q1 2026.
How has Vor Biopharma's short-term investments changed year-over-year?
Vor Biopharma's short-term investments increased by 3120.4% year-over-year, from $9.99M to $321.65M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.